Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.